An observational study in Sepsis and Septic Shock, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Assiut University · Observational
This prospective observational study aims to evaluate neutrophil activation markers and circulating citrullinated histone H3 levels in adult patients with sepsis or septic shock.
Sepsis is a life-threatening syndrome caused by a dysregulated host response to infection. Neutrophils play a central role through activation and release of neutrophil extracellular traps (NETs).
This observational study will assess neutrophil surface activation markers by flow cytometry and circulating citrullinated histone H3 levels by ELISA in adult patients with sepsis or septic shock enrolled within 24 hours of diagnosis, with measurements on the first and third day.
1,946 studies on the registry are indexed under Sepsis; 471 are open to participants now.
This study's planned enrollment of 85 is below the median of 160 across 957 observational studies indexed under Sepsis.
Browse Sepsis studies →Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients aged 18 years or older with sepsis or septic shock enrolled within 24 hours of diagnosis or admission to the intensive care unit at Assiut University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients with sepsis or septic shock undergoing assessment of neutrophil activation markers and citrullinated histone H3 levels.
Citrullinated histone H3 level
Mean plasma citrullinated histone H3 level measured by enzyme-linked immunosorbent assay.
Time frame: Baseline
CD66b expression
Mean percentage of neutrophils expressing CD66b measured by flow cytometry.
Time frame: Baseline
CD15 expression
Mean percentage of neutrophils expressing CD15 measured by flow cytometry.
Time frame: Baseline
Platelet count
Mean platelet count.
Time frame: Baseline
Number of deaths
Number of patients who die within 28 days.
Time frame: At 28 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 408 non-industry observational studies under Sepsis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 12 months is below that.
Counting every sponsor, half of 452 studies reached it within 29 months; a quarter within 12 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.